INDV Q3 2023 Earnings — Indivior Pharmaceuticals Inc Revenue & Financial Results | Market Cap Arena

INDVIndivior Pharmaceuticals Inc

$4B

Q3 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$271M+16.8% YoY

Gross Profit

$225M83.0% margin

Operating Income

-$183M-67.5% margin

Net Income

-$135M-49.8% margin

EPS (Diluted)

$-0.94

QoQ Revenue Growth

-1.8%

Cash Flow

Operating Cash Flow

$21M

Free Cash Flow

$19M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$1.9B

Total Liabilities

$1.9B

Stockholders' Equity

-$24M

Cash & Equivalents

$610M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$271M	$232M	+16.8%
Gross Profit	$225M	$192M	+17.2%
Operating Income	-$183M	$56M	-426.8%
Net Income	-$135M	$41M	-429.3%